Construction of a tumor immune microenvironment-related risk scoring model for prognosis of hepatocellular carcinoma
International Journal of Immunopathology and Pharmacology · 2025
DOI: 10.1177/03946320251333975 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Immunopathology and Pharmacology, 2025. Verfasst von Xinyi Li und 15 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Sciences & Bioengineering, Beijing Jiaotong University, Beijing, China. Hauptthemen laut MEDLINE: Tumor Microenvironment, Carcinoma, Hepatocellular, Liver Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
This study aims to develop a prognostic model for HCC based on TME-related factors.
Introduction
Hepatocellular carcinoma (HCC) is characterized by a poor prognosis, largely due to the complex and heterogeneous interactions between stromal and immune cells within the tumor microenvironment (TME).
Methods
Genome and transcriptome data, as well as clinical information of HCC patients, were obtained from the Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO). The TME score was evaluated using the “ESTIMATE” R package. Differentially expressed genes (DEGs) associated with TME phenotype were analyzed using the LIMMA R-package. Survival outcomes were compared using Kaplan–Meier curves with log-rank test and Cox proportional hazards model. Protein-Protein Interaction (PPI) networks integrated with multivariate survival and LASSO analyses were utilized to identify TME-related hub genes for a risk score model. A nomogram predicting prognosis of HCC patients was developed through four independent cohorts.
Results
The TME scores showed a negative correlation with tumor progression and survival in HCC patients. We identified 50 core genes with high connectivity in the PPI network, as along with 33 key DEGs associated with survival in HCC. Intersection analysis revealed six hub genes - CXCL8 , CXCL1 , CCR7 , IL7R , MMP9 , and CD69 . The risk score based on these six TME-related hub genes was significantly associated with overall survival and clinicopathological characteristics of HCC patients. Furthermore, the nomogram demonstrated its ability to discriminate HCC patients from healthy individuals using peripheral blood mononuclear cells.
Conclusion
We have developed a TME-related risk scoring model for HCC patients and identified six hub gene panel that serve as a potential biomarker for personalized prognosis of immunotherapy and non-invasive diagnostics of HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Life Sciences & Bioengineering, Beijing Jiaotong University, Beijing, China.
- School of Stomatology, Xinjiang Medical University, Urumqi, Xinjiang, China.
ORCID-Profile: Jiaqiang Huang
Zitieren
APA
Li, X., Qin, Z., Chen, H., Chen, D., Alimu, N., Li, D., Cheng, X., Yan, Q., Zhang, L., Liu, X., Zhou, Z., Zhu, J., Ma, H., Pei, X., Xu, H., & Huang, J. (2025). Construction of a tumor immune microenvironment-related risk scoring model for prognosis of hepatocellular carcinoma. International Journal of Immunopathology and Pharmacology. https://doi.org/10.1177/03946320251333975
Vancouver
Li X, Qin Z, Chen H, Chen D, Alimu N, Li D, et al. Construction of a tumor immune microenvironment-related risk scoring model for prognosis of hepatocellular carcinoma. International Journal of Immunopathology and Pharmacology. 2025. doi:10.1177/03946320251333975
BibTeX
@article{Li2025,
author = {Li, Xinyi and Qin, Zifan and Chen, Haozhi and Chen, Daichuan and Alimu, Nafisa and Li, Duoduo and Cheng, Xiyu and Yan, Qiong and Zhang, Lishu and Liu, Xingwei and Zhou, Zitong and Zhu, Jiayi and Ma, Hangqi and Pei, Xinyue and Xu, Hanli and Huang, Jiaqiang},
title = {Construction of a tumor immune microenvironment-related risk scoring model for prognosis of hepatocellular carcinoma},
journal = {International Journal of Immunopathology and Pharmacology},
year = {2025},
doi = {10.1177/03946320251333975}
}
EUVIMED